{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:59:15Z","timestamp":1790009955623,"version":"4.0.1"},"reference-count":77,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:p>Background: Multiple studies have reported brain lipidomic abnormalities in Alzheimer\u2019s disease (AD) that affect glycerophospholipids, sphingolipids, and fatty acids. However, there is no consensus regarding the nature of these abnormalities, and it is unclear if they relate to disease progression. Objective: Monogalactosyl diglycerides (MGDGs) are a class of lipids which have been recently detected in the human brain. We sought to measure their levels in postmortem human brain and determine if these levels correlate with the progression of the AD-related traits. Methods: We measured MGDGs by ultrahigh performance liquid chromatography tandem mass spectrometry in postmortem dorsolateral prefrontal cortex gray matter and subcortical corona radiata white matter samples derived from three cohorts of participants: the Framingham Heart Study, the Boston University Alzheimer\u2019s Disease Research Center, and the Arizona Study of Aging and Neurodegenerative Disorders\/Brain and Body Donation Program (total n\u200a=\u200a288). Results: We detected 40 molecular species of MGDGs (including diacyl and alkyl\/acyl compounds) and found that the levels of 29 of them, as well as total MGDG levels, are positively associated with AD-related traits including pathologically confirmed AD diagnosis, clinical dementia rating, Braak and Braak stage, neuritic plaque score, phospho-Tau AT8 immunostaining density, levels of phospho-Tau396 and levels of A\u03b240. Increased MGDG levels were present in both gray and white matter, indicating that they are widespread and likely associated with myelin-producing oligodendrocytes\u2014the principal cell type of white matter. Conclusions: Our data implicate the MGDG metabolic defect as a central correlate of clinical and pathological progression in AD.<\/jats:p>","DOI":"10.3233\/jad-230543","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:18:56Z","timestamp":1694776736000},"page":"1623-1634","source":"Crossref","is-referenced-by-count":12,"title":["Cerebral Gray and White Matter Monogalactosyl Diglyceride Levels Rise with the Progression of Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"95","author":[{"given":"Jan Krzysztof","family":"Blusztajn","sequence":"first","affiliation":[{"name":"Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"},{"name":"Boston University Alzheimer\u2019s Disease Research Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgul","family":"Aytan","sequence":"additional","affiliation":[{"name":"Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"},{"name":"Boston University Alzheimer\u2019s Disease Research Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thekkelnaycke","family":"Rajendiran","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany J.","family":"Mellott","sequence":"additional","affiliation":[{"name":"Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanu","family":"Soni","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Burant","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geidy E.","family":"Serrano","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghuang","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School, Worcester, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor D.","family":"Stein","sequence":"additional","affiliation":[{"name":"Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"},{"name":"Boston University Alzheimer\u2019s Disease Research Center, Boston, MA, USA"},{"name":"VA Boston Healthcare System, U.S. Department of Veteran Affairs, Jamaica Plain, MA, USA"},{"name":"VA Bedford Healthcare System, U.S. Department of Veteran Affairs, Bedford, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230543_ref1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JAD-230543_ref2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41582-021-00529-1","article-title":"The human connectome in Alzheimer disease - relationship to biomarkers and genetics","volume":"17","author":"Yu","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-230543_ref3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(85)92114-2","article-title":"Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer\u2019s brain","volume":"1","author":"Barany","year":"1985","journal-title":"Lancet"},{"key":"10.3233\/JAD-230543_ref4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archneur.1988.00520340047010","article-title":"Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer\u2019s disease","volume":"45","author":"Pettegrew","year":"1988","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230543_ref5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0006-8993(90)90030-F","article-title":"Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer\u2019s disease but not of Down\u2019s syndrome patients","volume":"536","author":"Blusztajn","year":"1990","journal-title":"Brain Res"},{"key":"10.3233\/JAD-230543_ref6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1073\/pnas.89.5.1671","article-title":"Evidence for a membrane defect in Alzheimer disease brain","volume":"89","author":"Nitsch","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230543_ref7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-8993(95)00931-F","article-title":"Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer\u2019s disease brain","volume":"698","author":"Ginsberg","year":"1995","journal-title":"Brain Res"},{"key":"10.3233\/JAD-230543_ref8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1023\/A:1027380331807","article-title":"Membrane phospholipid alterations in Alzheimer\u2019s disease: Deficiency of ethanolamine plasmalogens","volume":"22","author":"Farooqui","year":"1997","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-230543_ref9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00005072-199907000-00008","article-title":"Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease","volume":"58","author":"Guan","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-230543_ref10","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1046\/j.1471-4159.2001.00332.x","article-title":"Plasmalogen deficiency in early Alzheimer\u2019s disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry","volume":"77","author":"Han","year":"2001","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230543_ref11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1023\/A:1011603916962","article-title":"Brain membrane phospholipid alterations in Alzheimer\u2019s disease","volume":"26","author":"Pettegrew","year":"2001","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-230543_ref12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3233\/JAD-2011-101608","article-title":"Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer\u2019s disease prefrontal cortex","volume":"24","author":"Igarashi","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230543_ref13","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1038\/srep07130","article-title":"DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer\u2019s disease","volume":"4","author":"Yuki","year":"2014","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-230543_ref14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12017-020-08636-w","article-title":"Lipidomic analysis of postmortem prefrontal cortex phospholipids reveals changes in choline plasmalogen containing docosahexaenoic acid and stearic acid between cases with and without Alzheimer\u2019s disease","volume":"23","author":"Otoki","year":"2021","journal-title":"Neuromolecular Med"},{"key":"10.3233\/JAD-230543_ref15","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/alz.12714","article-title":"The landscape of metabolic brain alterations in Alzheimer\u2019s disease","volume":"19","author":"Batra","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230543_ref16","doi-asserted-by":"crossref","first-page":"981868","DOI":"10.3389\/fnagi.2022.981868","article-title":"Serine ether glycerophospholipids: Decrements in the frontal cortex associated with mild cognitive impairment and Alzheimer\u2019s disease","volume":"14","author":"Wood","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-230543_ref17","doi-asserted-by":"crossref","first-page":"e1002482","DOI":"10.1371\/journal.pmed.1002482","article-title":"Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study","volume":"15","author":"Varma","year":"2018","journal-title":"PLoS Med"},{"key":"10.3233\/JAD-230543_ref18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1471-4159.2002.00997.x","article-title":"Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer\u2019s disease: Potential role in disease pathogenesis","volume":"82","author":"Han","year":"2002","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230543_ref19","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0305799101","article-title":"Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer\u2019s disease","volume":"101","author":"Cutler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230543_ref20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11064-007-9297-x","article-title":"Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer\u2019s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer\u2019s disease?","volume":"32","author":"Katsel","year":"2007","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-230543_ref21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.brainres.2007.10.066","article-title":"Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: Consequences to morphology and viability on enzyme suppression in cultured primary neurons","volume":"1191","author":"Marks","year":"2008","journal-title":"Brain Res"},{"key":"10.3233\/JAD-230543_ref22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-2011-111202","article-title":"Increased ceramide in brains with Alzheimer\u2019s and other neurodegenerative diseases","volume":"29","author":"Filippov","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230543_ref23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0278-5846(86)90014-X","article-title":"Multiple biochemical deficits in both gray and white matter of Alzheimer brains","volume":"10","author":"Gottfries","year":"1986","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.3233\/JAD-230543_ref24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0404.1989.tb03886.x","article-title":"Decreased myelin lipids in Alzheimer\u2019s disease and vascular dementia","volume":"80","author":"Wallin","year":"1989","journal-title":"Acta Neurol Scand"},{"key":"10.3233\/JAD-230543_ref25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/jnc.12368","article-title":"Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer\u2019s disease: An early event in disease pathogenesis","volume":"127","author":"Cheng","year":"2013","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230543_ref26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03160049","article-title":"Gangliosides in the brain in adult Down\u2019s syndrome and Alzheimer\u2019s disease","volume":"11","author":"Brooksbank","year":"1989","journal-title":"Mol Chem Neuropathol"},{"key":"10.3233\/JAD-230543_ref27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0197-0186(92)90058-Y","article-title":"Cortical distribution of gangliosides in Alzheimer\u2019s disease","volume":"20","author":"Kracun","year":"1992","journal-title":"Neurochem Int"},{"key":"10.3233\/JAD-230543_ref28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1046\/j.1471-4159.1994.62031039.x","article-title":"Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II)","volume":"62","author":"Svennerholm","year":"1994","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230543_ref29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4615-1857-0_8","article-title":"Differential changes in regional brain ganglioside and neutral glycosphingolipid contents in Alzheimer\u2019s disease","volume":"363","author":"Ng Ying Kin","year":"1995","journal-title":"Adv Exp Med Biol"},{"key":"10.3233\/JAD-230543_ref30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/1567205014666170117094038","article-title":"Brain gangliosides in Alzheimer\u2019s disease: Increased expression of cholinergic neuron-specific gangliosides","volume":"14","author":"Fukami","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-230543_ref31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/acschemneuro.9b00532","article-title":"Spatial lipidomics reveals region and long chain base specific accumulations of monosialogangliosides in amyloid plaques in familial Alzheimer\u2019s disease mice (5xFAD) brain","volume":"11","author":"Kaya","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-230543_ref32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/j.1471-4159.1992.tb10994.x","article-title":"Lipid composition in different regions of the brain in Alzheimer\u2019s disease\/senile dementia of Alzheimer\u2019s type","volume":"59","author":"S\u00f6derberg","year":"1992","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230543_ref33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neulet.2012.04.019","article-title":"Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer\u2019s disease","volume":"516","author":"Kosicek","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-230543_ref34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s42003-022-04011-6","article-title":"Multi-Omic analyses characterize the ceramide\/sphingomyelin pathway as a therapeutic target in Alzheimer\u2019s disease","volume":"5","author":"Baloni","year":"2022","journal-title":"Commun Biol"},{"key":"10.3233\/JAD-230543_ref35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF02536067","article-title":"Fatty acid composition of brain phospholipids in aging and in Alzheimer\u2019s disease","volume":"26","author":"S\u00f6derberg","year":"1991","journal-title":"Lipids"},{"key":"10.3233\/JAD-230543_ref36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/brain\/116.3.717","article-title":"Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer\u2019s disease and control subjects","volume":"116","author":"Skinner","year":"1993","journal-title":"Brain"},{"key":"10.3233\/JAD-230543_ref37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-2012-110629","article-title":"Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer\u2019s disease","volume":"29","author":"Cunnane","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230543_ref38","doi-asserted-by":"crossref","first-page":"e1002266","DOI":"10.1371\/journal.pmed.1002266","article-title":"Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study","volume":"14","author":"Snowden","year":"2017","journal-title":"PLoS Med"},{"key":"10.3233\/JAD-230543_ref39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/metabo8040069","article-title":"Evidence that parietal lobe fatty acids may be more profoundly affected in moderate Alzheimer\u2019s disease (AD) pathology than in severe AD pathology","volume":"8","author":"Nasaruddin","year":"2018","journal-title":"Metabolites"},{"key":"10.3233\/JAD-230543_ref40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0005-2760(67)90083-5","article-title":"Monogalactosyl diglyceride: A new neurolipid","volume":"144","author":"Steim","year":"1967","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-230543_ref41","first-page":"398","article-title":"The association of the galactosyl diglycerides of nerve tissue with myelination","volume":"40","author":"Pieringer","year":"1973","journal-title":"Prog Brain Res"},{"key":"10.3233\/JAD-230543_ref42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1471-4159.1974.tb06882.x","article-title":"The biosynthesis and concentration of galactosyl diglyceride in glial and neuronal enriched fractions of actively myelinating rat brain","volume":"22","author":"Deshmukh","year":"1974","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230543_ref43","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/bi00850a049","article-title":"The metabolism of glyceride glycolipids. II. Biosynthesis of monogalactosyl diglyceride from uridine diphosphate galactose and diglyceride in brain","volume":"7","author":"Wenger","year":"1968","journal-title":"Biochemistry"},{"issue":"Pt 2","key":"10.3233\/JAD-230543_ref44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1042\/bj3170589","article-title":"Synthesis of non-hydroxy-galactosylceramides and galactosyldiglycerides by hydroxy-ceramide galactosyltransferase","volume":"317","author":"van der Bijl","year":"1996","journal-title":"Biochem J"},{"key":"10.3233\/JAD-230543_ref45","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1021\/bi00862a026","article-title":"A comprehensive study of the postnatal changes in the concentration of the lipids of developing rat brain","volume":"6","author":"Wells","year":"1967","journal-title":"Biochemistry"},{"key":"10.3233\/JAD-230543_ref46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.plipres.2018.08.002","article-title":"Properties, metabolism and roles of sulfogalactosylglycerolipid in male reproduction","volume":"72","author":"Tanphaichitr","year":"2018","journal-title":"Prog Lipid Res"},{"key":"10.3233\/JAD-230543_ref47","first-page":"403","article-title":"Human brain lipidomics: Utilities of chloride adducts in flow injection analysis","volume":"11","author":"Wood","year":"2021","journal-title":"Life (Basel)"},{"key":"10.3233\/JAD-230543_ref48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2174\/156720512801322609","article-title":"The Framingham Brain Donation Program: Neuropathology along the cognitive continuum","volume":"9","author":"Au","year":"2012","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-230543_ref49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jnen\/nly049","article-title":"The revised national Alzheimer\u2019s coordinating center\u2019s neuropathology form-available data and new analyses","volume":"77","author":"Besser","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-230543_ref50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-015-0148-8","article-title":"Assessing clinicopathological correlation in chronic traumatic encephalopathy: Rationale and methods for the UNITE study","volume":"7","author":"Mez","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-230543_ref51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00005072-199911000-00004","article-title":"Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease","volume":"58","author":"Newell","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-230543_ref52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnen\/nlw026","article-title":"Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum","volume":"75","author":"Serrano-Pozo","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-230543_ref53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/neup.12189","article-title":"Arizona study of aging and neurodegenerative disorders and brain and body donation program","volume":"35","author":"Beach","year":"2015","journal-title":"Neuropathology"},{"key":"10.3233\/JAD-230543_ref54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ekir.2016.08.007","article-title":"Lipidomic signature of progression of chronic kidney disease in the chronic renal insufficiency cohort","volume":"1","author":"Afshinnia","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.3233\/JAD-230543_ref55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1681\/ASN.2017030350","article-title":"Impaired beta-oxidation and altered complex lipid fatty acid partitioning with advancing CKD","volume":"29","author":"Afshinnia","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.3233\/JAD-230543_ref56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12931-018-0758-3","article-title":"Associations of the plasma lipidome with mortality in the acute respiratory distress syndrome: A longitudinal cohort study","volume":"19","author":"Maile","year":"2018","journal-title":"Respir Res"},{"key":"10.3233\/JAD-230543_ref57","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/alz.12502","article-title":"Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer\u2019s disease","volume":"18","author":"Stathas","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230543_ref58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease - the gateway to precision medicine","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-230543_ref59","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.neuron.2022.03.004","article-title":"ApoE cascade hypothesis in the pathogenesis of Alzheimer\u2019s disease and related dementias","volume":"110","author":"Martens","year":"2022","journal-title":"Neuron"},{"key":"10.3233\/JAD-230543_ref60","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/brain\/111.6.1425","article-title":"White matter changes in dementia of Alzheimer\u2019s type. Biochemical and neuropathological correlates","volume":"111","author":"Englund","year":"1988","journal-title":"Brain"},{"key":"10.3233\/JAD-230543_ref61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1017\/neu.2015.18","article-title":"Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer\u2019s disease subjects","volume":"27","author":"Wood","year":"2015","journal-title":"Acta Neuropsychiatr"},{"key":"10.3233\/JAD-230543_ref62","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2023.0217"},{"key":"10.3233\/JAD-230543_ref63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13024-017-0219-3","article-title":"Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer\u2019s disease","volume":"12","author":"McKenzie","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-230543_ref64","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jalz.2017.11.010","article-title":"DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer\u2019s disease and dementia","volume":"14","author":"Tse","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230543_ref65","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jalz.2017.09.012","article-title":"Conserved brain myelination networks are altered in Alzheimer\u2019s and other neurodegenerative diseases","volume":"14","author":"Allen","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230543_ref66","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.neuron.2022.03.008","article-title":"Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer\u2019s disease","volume":"110","author":"Sadick","year":"2022","journal-title":"Neuron"},{"key":"10.3233\/JAD-230543_ref67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41593-022-01104-7","article-title":"A shared disease-associated oligodendrocyte signature among multiple CNS pathologies","volume":"25","author":"Kenigsbuch","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-230543_ref68","doi-asserted-by":"crossref","first-page":"e2206083119","DOI":"10.1073\/pnas.2206083119","article-title":"Metabolome-wide association study on ABCA7 indicates a role of ceramide metabolism in Alzheimer\u2019s disease","volume":"119","author":"Dehghan","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230543_ref69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41467-017-02361-y","article-title":"The mechanism of glycosphingolipid degradation revealed by a GALC-SapA complex structure","volume":"9","author":"Hill","year":"2018","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-230543_ref70","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/08830738030180090201","article-title":"Globoid cell leukodystrophy (Krabbe\u2019s disease): Update","volume":"18","author":"Suzuki","year":"2003","journal-title":"J Child Neurol"},{"key":"10.3233\/JAD-230543_ref71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s40478-019-0862-8","article-title":"Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer\u2019s disease and aged brains: Increased levels correlate with neuropathology","volume":"7","author":"Mendsaikhan","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-230543_ref72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cca.2019.03.243","article-title":"Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer\u2019s disease","volume":"494","author":"Andersson","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.3233\/JAD-230543_ref73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.plipres.2019.04.003","article-title":"Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease","volume":"74","author":"Paul","year":"2019","journal-title":"Prog Lipid Res"},{"key":"10.3233\/JAD-230543_ref74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/antiox12020293","article-title":"Ether lipid-mediated antioxidant defense in Alzheimer\u2019s disease","volume":"12","author":"Jove","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.3233\/JAD-230543_ref75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00401-011-0836-9","article-title":"Peroxisomal alterations in Alzheimer\u2019s disease","volume":"122","author":"Kou","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230543_ref76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JAD-2011-111163","article-title":"Potential roles of peroxisomes in Alzheimer\u2019s disease and in dementia of the Alzheimer\u2019s type","volume":"29","author":"Lizard","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230543_ref77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40478-023-01567-0","article-title":"Rise and fall of peroxisomes during Alzheimer s disease: A pilot study in human brains","volume":"11","author":"Semikasev","year":"2023","journal-title":"Acta Neuropathol Commun"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:32Z","timestamp":1777370912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":77,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-230543","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]}}}